文献速递咽喉与嗓音

自体成纤维细胞治疗声带瘢痕与年龄相关萎缩:随机临床试验

Autologous fibroblasts for vocal scars and age-related atrophy: A randomized clinical trial.
PubMed 文献 · Laryngoscope · 2019-12-05

这项随机双盲安慰剂对照多中心II期试验评估自体培养成纤维细胞(ACF)治疗声带瘢痕和年龄相关声带萎缩(ARVA)相关发声障碍的安全性和有效性。

要点

  • ACF注射可安全改善声带瘢痕和ARVA患者的黏膜波。
  • ARVA组在4和8个月时黏膜波较对照组显著改善。
  • 声带瘢痕组12个月时感知分析较对照组显著改善。

核心结论

  • 在本队列中,向声带固有层注射ACF是安全的,并显著改善了声带瘢痕和ARVA患者的黏膜波。
  • ACF可能有望用于重建固有层。

研究设计与样本

  • 随机、双盲、安慰剂对照、多中心II期试验。
  • ACF从每例受试者耳后皮肤打孔活检组织扩增;随机分组比例为2:1(治疗组对安慰剂组)。
  • 每侧声带以4周间隔进行三次注射,每次注射1-2×10^7个细胞或安慰剂生理盐水。
  • 随访在第4、8和12个月进行。
  • 主要结局为黏膜波改善;次要结局包括VHI-30、患者报告的发声质量结局和嗓音感知分析。

主要发现

  • ACF治疗后第4、8和12个月,声带瘢痕组和ARVA组的黏膜波分级均较基线显著改善。
  • 与对照组相比,ARVA组在4和8个月时黏膜波显著改善。
  • 与对照组相比,声带瘢痕组在ACF治疗后12个月时感知分析显著改善。
  • 声带瘢痕组报告发声质量较基线显著改善;两组的VHI和专家评分嗓音分级均有改善但未达显著性;未观察到与成纤维细胞注射相关的不良事件。

临床怎么用

  • 对于声带瘢痕和年龄相关声带萎缩患者,声带固有层ACF注射在本试验中显示安全且可改善黏膜波。
  • ARVA患者在4和8个月时黏膜波较对照组显著改善,声带瘢痕组在12个月时感知分析较对照组显著改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES/HYPOTHESIS: To assess the safety and efficacy of autologous cultured fibroblasts (ACFs) to treat dysphonia related to vocal fold scar and age-related vocal atrophy (ARVA). STUDY DESIGN: Randomized, double-blinded, placebo-controlled, multi-institutional, phase II trial. METHODS: ACFs were expanded from punch biopsies of the postauricular skin in each subject; randomization was 2:1 (treatment vs. placebo). Three injections of 1-2 × 107 cells or placebo saline was performed at 4-week intervals for each vocal fold. Follow-up was performed at 4, 8, and 12 months. The primary outcome was improved mucosal waves. Secondary outcomes included Voice Handicap Index (VHI)-30, patient reported voice quality outcomes, and perceptual analysis of voice. RESULTS: Fifteen subjects received ACF and six received saline injections. At 4, 8, and 12 months after ACF treatments, a significant improvement in mucosal wave grade relative to baseline was observed in both vocal scar and ARVA groups. Relative to control group, mucosal waves were significantly improved in the ARVA group at 4 and 8 months. Perceptual analysis significantly improved in the vocal scar group 12 months after ACF treatments compared to controls. Vocal scar group reported significantly improved vocal quality from baseline. VHI and expert rater voice grade improved in both groups, but did not achieve significance. No adverse events related to fibroblast injections were observed. CONCLUSIONS: In this cohort, injection of ACFs into the vocal fold lamina propria (LP) was safe and significantly improved mucosal waves in patients with vocal scar and ARVA. ACF may hold promise to reconstruct the LP. LEVEL OF EVIDENCE: 1 Laryngoscope, 130:2650-2658, 2020.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Ma Y, Long J, Amin MR, et al. Autologous fibroblasts for vocal scars and age-related atrophy: A randomized clinical trial. Laryngoscope. 2019. PMID: 31804729. doi:10.1002/lary.28453

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。